-
OnCusp Therapeutics’ CUSP06 Receives FDA Fast Track for Ovarian Cancer
•
Sino-US company OnCusp Therapeutics Inc. has announced that it has received Fast Track Designation (FTD) from the US Food and Drug Administration (FDA) for its CUSP06. CUSP06 is a Cadherin-6 targeting antibody-drug conjugate (CDH6 ADC). The targeted indication for this therapy is platinum-resistant ovarian cancer (PROC). Drug DetailsCUSP06, the CDH6…
-
OnCusp Therapeutics Secures Oversubscribed USD 100 Million Series A Financing for CDH6-Targeting ADC
•
OnCusp Therapeutics, a U.S.-based biopharmaceutical company, has closed an oversubscribed Series A financing round, raising USD 100 million. The round was led by Novo Holdings, OrbiMed, and F-Prime Capital, with significant contributions from BioTrack Capital, a Chinese investor involved in OnCusp’s seed funding, Catalio Capital Management, Marshall Wace, Forge Life…
-
OnCusp Therapeutics Licenses Multitude’s CDH6 ADC for Global Development
•
US-based OnCusp Therapeutics has entered into a licensing agreement with China’s Multitude Therapeutics for the global development and commercialization of AMT-707 (CUSP06), a preclinical-stage cadherin-6 (CDH6) antibody-drug conjugate (ADC). OnCusp gains exclusive rights outside Greater China, while Multitude receives undisclosed upfront, milestone payments, and royalties. Scientific Rationale and Drug ProfileCDH6…
